0B68 Aplin, Andrew E. - Thomas Jefferson University - Thomas Jefferson University

Andrew E. Aplin, PhD

Contact Dr. Aplin

Kimmel Cancer Center
233 S. Tenth Street, Suite 522
Philadelphia, PA 19107

(215) 503-7296
(215) 923-9248 fax

Most Recent Peer-reviewed Publications

  1. Animal experimentation - questioned again!
  2. The value of thesis advisers
  3. NF-κB regulation of c-FLIP promotes TNFα-mediated RAF inhibitor resistance in melanoma
  4. What shall we do this year?
  5. Game of isoforms: PI3K β-sparing inhibitor is coming
  6. The value of thesis advisers
  7. Sestrin2 protein positively regulates AKT enzyme signaling and survival in human squamous cell carcinoma and melanoma cells
  8. Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor
  9. Resistance to RAF inhibitors revisited
  10. FOXD3 modulates migration through 0F79 direct transcriptional repression of TWIST1 in melanoma
  11. Unmet needs in melanoma research
  12. Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma
  13. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors
  14. Erratum: Hippo: Hungry, hungry for melanoma invasion (Journal of Investigative Dermatology)
  15. Hippo: Hungry, hungry for melanoma invasion
  16. Adaptive resistance to RAF inhibitors in melanoma
  17. Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma
  18. In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors
  19. A statement on vemurafenib-resistant melanoma
  20. Meeting report: The future of preclinical mouse models in melanoma treatment is now.